Hypothyroidism and Dyshormonogenesis Induced by D-Penicillamine in Children with Wilson's Disease and Healthy Infants Born to a Mother with Wilson's Disease

被引：8
|
作者：
Hanukoglu, Aaron [1 ,4 ]
Curiel, Batya [1 ,4 ]
Berkowitz, Drora [5 ]
Levine, Arieh [2 ,4 ]
Sack, Joseph [6 ]
Lorberboym, Mordehai [3 ,4 ]
机构：
[1] E Wolfson Med Ctr, Div Pediat Endocrinol, IL-58100 Holon, Israel
[2] E Wolfson Med Ctr, Div Pediat Gastroenterol, IL-58100 Holon, Israel
[3] E Wolfson Med Ctr, Inst Nucl Med, IL-58100 Holon, Israel
[4] Tel Aviv Univ, Sackler Sch Med, Haifa, Israel
[5] Rambam Med Ctr, Haifa, Israel
[6] Minist Hlth, Jerusalem, Israel
来源：
JOURNAL OF PEDIATRICS | 2008年 / 153卷 / 06期
关键词：
D O I：
10.1016/j.jpeds.2008.06.015
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Two siblings born to a mother with Wilson's disease, who was taking D-penicillamine, developed transient goitrous hypothyroidism. A prospective evaluation of 5 patients with Wilson's disease taking and not talking D-penicillamine for as long as 9.5 years showed subclinical hypothyroidism. D-penicillamine probably inhibited thyroperoxidase activity in utero in healthy infants and during childhood in patients with Wilson's disease. (J Pediatr 2008.153:864-6)
引用
收藏
页码：864 / 866
页数：3
相关论文
共 50 条
  • [41] Oral Complications Associated With D-Penicillamine Treatment for Wilson Disease: A Clinicopathologic Report
    Tovaru, Serban
    Parlatescu, Ioannina
    Dumitriu, Anca-Silvia
    Bucur, Alexandru
    Kaplan, Ilana
    JOURNAL OF PERIODONTOLOGY, 2010, 81 (08) : 1231 - 1236
  • [42] Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients
    Lee, Eun Joo
    Woo, Min Hyung
    Moon, Jin Soo
    Ko, Jae Sung
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [43] D-penicillamine-induced ANA (+) ANCA (+) vasculitis in pediatric patients with Wilson's disease
    Lee, Yeonhee
    Lee, Sang Taek
    Cho, Heeyeon
    CLINICAL NEPHROLOGY, 2016, 85 (05) : 296 - 300
  • [44] D-penicillamine-induced lupus erythematosus as an adverse reaction of treatment of Wilson's Disease
    Antos, Agnieszka
    Litwin, Tomasz
    Przybylkowski, Adam
    Skowronska, Marta
    Kurkowska-Jastrzebska, Iwona
    Czlonkowska, Anna
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2021, 55 (06) : 595 - 597
  • [45] Penicillamine-induced lethal status dystonicus in a patient with Wilson's disease
    Svetel, M
    Sternic, N
    Pejovic, S
    Kostic, VS
    MOVEMENT DISORDERS, 2001, 16 (03) : 568 - 569
  • [46] Pompholyx-Like Eruptions Induced by Penicillamine in a Patient with Wilson's Disease
    Devassy, Diana Elizabeth
    Harshad, Sujata Raj
    Devarbhai, Harshad
    INDIAN JOURNAL OF DERMATOLOGY, 2019, 64 (04) : 321 - 323
  • [47] Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease
    Jing Zhang
    Lulu Xiao
    Wenming Yang
    BMC Neurology, 20
  • [48] Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease
    Zhang, Jing
    Xiao, Lulu
    Yang, Wenming
    BMC NEUROLOGY, 2020, 20 (01)
  • [49] Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators
    Delangle, Pascale
    Mintz, Elisabeth
    DALTON TRANSACTIONS, 2012, 41 (21) : 6359 - 6370
  • [50] Correction to: Adverse Events with d-penicillamine Therapy in Hepatic Wilson’s Disease: A Single-Center Retrospective Audit
    Sanjay Kumar
    Biswa Ranjan Patra
    Mohammed Irtaza
    Praveen Kumar Rao
    Suprabhat Giri
    Harish Darak
    Amrit Gopan
    Aditya Kale
    Akash Shukla
    Clinical Drug Investigation, 2022, 42 : 281 - 282
12345